Aura Biosciences (NASDAQ:AURA) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Aura Biosciences (NASDAQ:AURA) issued its quarterly earnings results on Tuesday. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02, Zacks reports.

Aura Biosciences Stock Performance

Aura Biosciences stock traded down $0.26 during trading hours on Wednesday, reaching $10.39. 42,103 shares of the company’s stock traded hands, compared to its average volume of 175,165. The firm’s 50 day moving average is $9.69 and its 200-day moving average is $8.49. Aura Biosciences has a fifty-two week low of $6.63 and a fifty-two week high of $12.38.

Insider Activity at Aura Biosciences

In other news, CFO Julie B. Feder sold 25,131 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the sale, the chief financial officer now directly owns 134,276 shares of the company’s stock, valued at $1,615,340.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.03, for a total transaction of $302,325.93. Following the completion of the sale, the chief financial officer now owns 134,276 shares of the company’s stock, valued at approximately $1,615,340.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the transaction, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,259 shares of company stock worth $780,699 over the last ninety days. Company insiders own 5.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on AURA shares. HC Wainwright lifted their target price on Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. BTIG Research boosted their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Finally, JMP Securities raised their target price on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.